← ANALYST RATINGS · TIPRANKS
Armata Pharmaceuticals (ARMP): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $17.50, the highest $20.00, the lowest $15.00. The average is +419.3% from the last price of $3.37.
Analyst ratings 2
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 → $3.00+20.0% | Hold | −11.0% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $3.00+20.0% | Hold | −11.0% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $3.00+20.0% | Hold | −11.0% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.00 → $2.50−16.7% | Hold | −25.8% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 → $2.50−16.7% | Hold | −25.8% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 → $2.50−16.7% | Hold | −25.8% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $3.00−25.0% | Hold | −11.0% | Reiterated | 14.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.00−25.0% | Hold | −11.0% | Reiterated | 14.10.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.00−25.0% | Hold | −11.0% | Reiterated | 14.10.26on TipRanks 07:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $3.00−25.0% | Hold | −11.0% | Reiterated | 14.10.26on TipRanks 07:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $3.00−25.0% | Hold | −11.0% | Reiterated | 14.10.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.00−25.0% | Hold | −11.0% | Reiterated | 14.10.26on TipRanks 07:05 | — | |
| Debanjana Chatterjee★★★★★★★★★★#121 · hits 68% · avg +45.6% | JonesTrading | $20.00 | Buy | +493.5% | Reiterated | 27.09.26on TipRanks 10:30 | +1.8%next day −4.8% · 5 days −4.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.50 → $4.00−11.1% | Hold | +18.7% | Reiterated | 23.09.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.50 → $4.00−11.1% | Hold | +18.7% | Reiterated | 23.09.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.50 → $4.00−11.1% | Hold | +18.7% | Reiterated | 23.09.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.50 → $4.00−11.1% | Hold | +18.7% | Reiterated | 23.09.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.50 → $4.00−11.1% | Hold | +18.7% | Reiterated | 23.09.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.50 → $4.00−11.1% | Hold | +18.7% | Reiterated | 23.09.26on TipRanks 12:05 | — | |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $15.00 | Buy | +345.1% | Reiterated | 23.09.26on TipRanks Sep 22 06:35 | −1.4%next day −12.6% · 5 days −13.3% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Armata Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $17.50 at a price of $3.67 (+376.8%); now: $17.50 at $3.37 (+419.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 4 | 6 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.56 (from $-0.57 to $-0.54). Last quarter: $-0.27.
Sales
Next quarter’s sales estimate — $0M (from $0M to $1M). Last quarter: $3M.
Best top-analyst consensus in the sector · Healthcare
About Armata Pharmaceuticals
- CEO: Deborah L. Birx
- Employees: 61
- 4503 Glencoe Avenue, Los Angeles, CA, 90066, US
- www.armatapharma.com
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Data from the stock’s TipRanks forecast page, read 281 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗